Feature | January 20, 2009

CRi to Distribute Fluorescence In Vivo Imaging Agents in North America

January 20, 2009 - Cambridge Research & Instrumentation (CRi) and VisEn Medical signed a non-exclusive agreement to enable CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America, in an effort to broaden the use of leading fluorescence in vivo imaging technologies, applications and standards in research and drug development.

CRi has a history of working in multi-spectral fluorescence in vivo imaging and fluorescence microscopy imaging systems, and reportedly has a significant customer base with a broad range of applications in life science research today. The distributor will bring in VisEn's fluorescent in vivo agents and labels to iCR’s Maestro multispectral fluorescence imaging system customers.

VisEn’s proprietary in vivo imaging agents and labels are designed to provide a robust and broad range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways in vivo, with several more new agents expected for launch in 2009. Key research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease and pulmonary diseases, all in the context of the living animal.

VisEn’s agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro system with its powerful proprietary multispectral imaging technology. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

For more information: www.visenmedical.com and www.cri-inc.com

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
Overlay Init